Processa Pharmaceuticals Inc (NASDAQ:PCSA) price on Thursday, May 01, fall -2.99% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.25.
A look at the stock’s price movement, the close in the last trading session was $0.26, moving within a range at $0.2275 and $0.2565. The beta value (5-Year monthly) was 1.041. Turning to its 52-week performance, $3.10 and $0.15 were the 52-week high and 52-week low respectively. Overall, PCSA moved -39.30% over the past month.
Processa Pharmaceuticals Inc’s market cap currently stands at around $1.32 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-19.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PCSA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend PCSA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PCSA’s current price about -1.74% and -33.83% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.90, while 7-day volatility ratio is 13.58% and 30.71% in the 30-day chart. Further, Processa Pharmaceuticals Inc (PCSA) has a beta value of 1.35, and an average true range (ATR) of 0.05. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $9 and high of $9. Looking at the price targets, the low is -3500.0% off current price level while to achieve the yearly target high, price needs to move -3500.0%. Nonetheless, investors will most likely welcome a -3500.0% jump to $9 which is the analysts’ median price.
If we refocus on Processa Pharmaceuticals Inc (NASDAQ:PCSA), historical trading data shows that trading volumes averaged 2.04 over the past 10 days and 2.21 million over the past 3 months. The company’s latest data on shares outstanding shows there are 5.27 million shares.
The 12.12% of Processa Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 1.88% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.01 million on 2025-04-15, giving us a short ratio of 0.39. The data shows that as of 2025-04-15 short interest in Processa Pharmaceuticals Inc (PCSA) stood at 4266.0 of shares outstanding, with shares short rising to 95265.0 registered in 2025-03-14. Current price change has pushed the stock -71.70% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PCSA stock continues to rise going into the next quarter.
